Evaluating complete revascularization in patients with multivessel coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter study aims to assess clinical outcomes following complete revascularization using percutaneous coronary intervention (PCI) and optical coherence tomography (OCT) guidance in patients with multivessel coronary artery disease. The study focuses on individuals presenting with stable angina, silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS). The primary endpoint is a composite of major adverse cardiovascular and cerebrovascular events at one year post-procedure, with secondary endpoints extending to five years. Eligible patients include those aged 18 to 85 years with multivessel disease but without chronic total occlusions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years, ≤85 years
2. The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki
3. Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.
4. The patient is willing and able to cooperate with study procedures and required follow up visits
5. The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an EC approved written informed consent, including data privacy authorization

Exclusion Criteria:

1. Age \<18 years and \> 85 years.
2. Single coronary vessel disease.
3. No left anterior descending lesion.
4. Patients in cardiogenic shock.
5. Patients with STEMI.
6. Presence of a chronic total occlusion (CTO) defined as coronary lesion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 on initial angiography present for more than or equal to 3 months.
7. Left main coronary artery disease
8. Patients who cannot give informed consent or have a life expectancy of less than 12 months.
9. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y12 inhibitors.
10. Patients with an extreme LAD tortuosity imparing OCT catheter advancement
11. Enrollment in another study with another investigational device or drug trial that has not reached the primary endpoint. The patient may only be enrolled once in the PRESENT study.
12. Previous coronary artery bypass grafting (CABG).
13. Patient requiring additional cardiac surgery within 6 months.
14. Women of childbearing potential who do not have a negative pregnancy test result within 7 days before the procedure, women who are known to be pregnant, or who are breastfeeding.

Where it's running

• Erasmus Medical Center
  Rotterdam, South Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Roberto Diletti, MD PhD — Erasmus Medical Center
• Study coordinator: Roberto Diletti, MD PhD
• Email: r.diletti@erasmusmc.nl
• Phone: +31 (0)10 70 352 60

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

• DCB-based PCI vs DES-based PCI in multivessel coronary disease

  This study tests whether using a drug-coated balloon for PCI works as well as drug-eluting stents in people with disease in multiple coronary arteries.

  Recruiting Genoss Co., Ltd. · Ulsan · NCT07539324

• What affects bleeding control and how long you need to lie flat after femoral arterial sheath removal

  We will see if patient and procedure factors can predict how long ICU patients need compression and bed rest after femoral arterial sheath removal to prevent bleeding and hematoma.

  Recruiting National Taiwan University Hospital · Taipei · NCT07469397

• Doctors' and patients' preferences for PCI implantation devices

  This questionnaire tests what patients who have had PCI and the doctors who treat them prefer between drug-eluting stents and drug-coated balloons.

  Recruiting Xijing Hospital · Xi'an, Shannxi · NCT07378163

• How patients and doctors value different outcomes after coronary stent procedures

  This project asks patients who had a coronary stent (PCI) and the doctors who treat them to rate how important different possible outcomes are to see if their priorities match.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07378137

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.